Cancer is the second leading cause of death in the United States. Furthermore, it
contributes to a significant number of emergency department (ED) visits, and patients
with cancer are much more likely to bounce back to the ED than the general population.
Cancer patients are often immunosuppressed and commonly have altered physiology that
predisposes them to a variety of complex pathophysiologic conditions. In a renaissance
era of novel cancer therapies (including checkpoint inhibitors and chimeric antigen
receptor–modified T-cell [CAR-T] therapy), it is imperative that emergency physicians
(EPs) are educated on the common complications from cancer and cancer therapies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
